Cargando…
The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance
Breast cancer is the second leading cause of cancer-related death in women and is a complex disease with high intratumoral and intertumoral heterogeneity. Such heterogeneity is a major driving force behind failure of current therapies and development of resistance. Due to the limitations of conventi...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608750/ https://www.ncbi.nlm.nih.gov/pubmed/33872192 http://dx.doi.org/10.1101/gad.342287.120 |
_version_ | 1783604891996913664 |
---|---|
author | Nandi, Ajeya Chakrabarti, Rumela |
author_facet | Nandi, Ajeya Chakrabarti, Rumela |
author_sort | Nandi, Ajeya |
collection | PubMed |
description | Breast cancer is the second leading cause of cancer-related death in women and is a complex disease with high intratumoral and intertumoral heterogeneity. Such heterogeneity is a major driving force behind failure of current therapies and development of resistance. Due to the limitations of conventional therapies and inevitable emergence of acquired drug resistance (chemo and endocrine) as well as radio resistance, it is essential to design novel therapeutic strategies to improve the prognosis for breast cancer patients. Deregulated Notch signaling within the breast tumor and its tumor microenvironment (TME) is linked to poor clinical outcomes in treatment of resistant breast cancer. Notch receptors and ligands are also important for normal mammary development, suggesting the potential for conserved signaling pathways between normal mammary gland development and breast cancer. In this review, we focus on mechanisms by which Notch receptors and ligands contribute to normal mammary gland development and breast tumor progression. We also discuss how complex interactions between cancer cells and the TME may reduce treatment efficacy and ultimately lead to acquired drug or radio resistance. Potential combinatorial approaches aimed at disrupting Notch- and TME-mediated resistance that may aid in achieving in an improved patient prognosis are also highlighted. |
format | Online Article Text |
id | pubmed-7608750 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Cold Spring Harbor Laboratory Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-76087502021-05-01 The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance Nandi, Ajeya Chakrabarti, Rumela Genes Dev Review Breast cancer is the second leading cause of cancer-related death in women and is a complex disease with high intratumoral and intertumoral heterogeneity. Such heterogeneity is a major driving force behind failure of current therapies and development of resistance. Due to the limitations of conventional therapies and inevitable emergence of acquired drug resistance (chemo and endocrine) as well as radio resistance, it is essential to design novel therapeutic strategies to improve the prognosis for breast cancer patients. Deregulated Notch signaling within the breast tumor and its tumor microenvironment (TME) is linked to poor clinical outcomes in treatment of resistant breast cancer. Notch receptors and ligands are also important for normal mammary development, suggesting the potential for conserved signaling pathways between normal mammary gland development and breast cancer. In this review, we focus on mechanisms by which Notch receptors and ligands contribute to normal mammary gland development and breast tumor progression. We also discuss how complex interactions between cancer cells and the TME may reduce treatment efficacy and ultimately lead to acquired drug or radio resistance. Potential combinatorial approaches aimed at disrupting Notch- and TME-mediated resistance that may aid in achieving in an improved patient prognosis are also highlighted. Cold Spring Harbor Laboratory Press 2020-11-01 /pmc/articles/PMC7608750/ /pubmed/33872192 http://dx.doi.org/10.1101/gad.342287.120 Text en © 2020 Nandi and Chakrabarti; Published by Cold Spring Harbor Laboratory Press http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Review Nandi, Ajeya Chakrabarti, Rumela The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance |
title | The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance |
title_full | The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance |
title_fullStr | The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance |
title_full_unstemmed | The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance |
title_short | The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance |
title_sort | many facets of notch signaling in breast cancer: toward overcoming therapeutic resistance |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608750/ https://www.ncbi.nlm.nih.gov/pubmed/33872192 http://dx.doi.org/10.1101/gad.342287.120 |
work_keys_str_mv | AT nandiajeya themanyfacetsofnotchsignalinginbreastcancertowardovercomingtherapeuticresistance AT chakrabartirumela themanyfacetsofnotchsignalinginbreastcancertowardovercomingtherapeuticresistance AT nandiajeya manyfacetsofnotchsignalinginbreastcancertowardovercomingtherapeuticresistance AT chakrabartirumela manyfacetsofnotchsignalinginbreastcancertowardovercomingtherapeuticresistance |